logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Beremagene geperpavec for dystrophic epidermolysis bullosa

< Back

Beremagene geperpavec for dystrophic epidermolysis bullosa

Drugs

Skin Disease, Burns and Wound Care

April 2021


Dystrophic epidermolysis bullosa (DEB) is caused by a mutation in a collagen gene that controls skin strength and stability. This mutation can be inherited from one or both parents, which determines the severity of the condition (those who inherit the mutation from both parents have more severe symptoms). DEB symptoms develop from birth or early childhood and is characterised by painful skin blisters and scarring. Some people with DEB can have minor blisters mainly at areas that experience trauma such as hands, feet, arms and legs, whereas other people can have blistering externally and internally, which can cause many associated issues. Most people with DEB have blistering around and inside the mouth that affects eating and dental hygiene.
Beremagene geperpavec topical gel aims to treat DEB by delivering normal, functional collagen genes to the affected skin cells, by doing so this promotes wound-healing and reduces scarring. If licenced, beremagene geperpavec will offer the first DEB-specific treatment that addresses the underlying cause of the disease for paediatric and adult patients.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts